Smith, Moore & Co’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.22M | Sell |
5,672
-44
| -0.8% | -$44.6K | 0.38% | 58 |
|
|
2025
Q4 | $6.14M | Sell |
5,716
-449
| -7% | -$429K | 0.46% | 49 |
|
|
2025
Q3 | $4.7M | Buy |
6,165
+311
| +5% | +$231K | 0.36% | 64 |
|
|
2025
Q2 | $4.56M | Sell |
5,854
-591
| -9% | -$459K | 0.38% | 59 |
|
|
2025
Q1 | $5.32M | Sell |
6,445
-1,058
| -14% | -$880K | 0.49% | 41 |
|
|
2024
Q4 | $5.79M | Sell |
7,503
-784
| -9% | -$649K | 0.53% | 36 |
|
|
2024
Q3 | $7.34M | Sell |
8,287
-41
| -0.5% | -$36.9K | 0.7% | 27 |
|
|
2024
Q2 | $7.54M | Sell |
8,328
-748
| -8% | -$598K | 0.78% | 23 |
|
|
2024
Q1 | $7.06M | Buy |
9,076
+1,037
| +13% | +$738K | 0.75% | 22 |
|
|
2023
Q4 | $4.69M | Buy |
8,039
+315
| +4% | +$184K | 0.55% | 33 |
|
|
2023
Q3 | $4.15M | Buy |
7,724
+50
| +0.7% | +$25.8K | 0.55% | 35 |
|
|
2023
Q2 | $3.6M | Buy |
7,674
+1,353
| +21% | +$567K | 0.46% | 41 |
|
|
2023
Q1 | $2.17M | Buy |
6,321
+928
| +17% | +$313K | 0.3% | 75 |
|
|
2022
Q4 | $1.97M | Buy |
5,393
+58
| +1% | +$20.6K | 0.27% | 78 |
|
|
2022
Q3 | $1.73M | Sell |
5,335
-223
| -4% | -$70.7K | 0.26% | 81 |
|
|
2022
Q2 | $1.8M | Sell |
5,558
-801
| -13% | -$240K | 0.28% | 82 |
|
|
2022
Q1 | $1.82M | Buy |
6,359
+51
| +0.8% | +$13.1K | 0.25% | 80 |
|
|
2021
Q4 | $1.74M | Buy |
6,308
+341
| +6% | +$86.4K | 0.24% | 78 |
|
|
2021
Q3 | $1.38M | Buy |
5,967
+228
| +4% | +$56.3K | 0.21% | 90 |
|
|
2021
Q2 | $1.32M | Sell |
5,739
-20
| -0.3% | -$4.02K | 0.2% | 97 |
|
|
2021
Q1 | $1.08M | Buy |
5,759
+190
| +3% | +$37.2K | 0.17% | 121 |
|
|
2020
Q4 | $940K | Sell |
5,569
-601
| -10% | -$89.7K | 0.18% | 112 |
|
|
2020
Q3 | $913K | Buy |
6,170
+539
| +10% | +$83.4K | 0.19% | 102 |
|
|
2020
Q2 | $925K | Buy |
5,631
+877
| +18% | +$135K | 0.2% | 90 |
|
|
2020
Q1 | $659K | Buy |
4,754
+160
| +3% | +$22K | 0.17% | 115 |
|
|
2019
Q4 | $604K | Buy |
4,594
+1,207
| +36% | +$140K | 0.13% | 153 |
|
|
2019
Q3 | $379K | Sell |
3,387
-22
| -0.6% | -$2.45K | 0.08% | 212 |
|
|
2019
Q2 | $378K | Buy |
3,409
+923
| +37% | +$109K | 0.09% | 220 |
|
|
2019
Q1 | $323K | Sell |
2,486
-55
| -2% | -$6.69K | 0.08% | 235 |
|
|
2018
Q4 | $294K | Sell |
2,541
-2
| -0.1% | -$223 | 0.08% | 232 |
|
|
2018
Q3 | $273K | Buy |
2,543
+101
| +4% | +$10.1K | 0.06% | 269 |
|
|
2018
Q2 | $208K | Buy |
+2,442
| New | +$201K | 0.05% | 309 |
|
|
2018
Q1 | – | Sell |
-2,392
| Closed | -$202K | – | 335 |
|
|
2017
Q4 | $202K | Buy |
2,392
+1
| +0% | +$85 | 0.05% | 285 |
|
|
2017
Q3 | $205K | Buy |
+2,391
| New | +$196K | 0.06% | 283 |
|
Other funds holding LLY
VCM
VPM
Smith, Moore & Co's LLY Position: Q1 2026 in Review
Smith, Moore & Co reduced its Eli Lilly (LLY) stake by 0.77% in Q1 2026, selling an estimated $44.6K and leaving 5,672 shares worth $5.22M. The position accounts for 0.38% of the portfolio, ranked #58.
Smith, Moore & Co first reported a position in LLY in Q3 2017 and has held it in 34 quarters since. The position peaked at $7.54M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Smith, Moore & Co held 5,672 shares of Eli Lilly worth $5.22M as of Q1 2026.
- Smith, Moore & Co sold 44 Eli Lilly shares in Q1 2026, an estimated $44.6K.
- Eli Lilly made up 0.38% of Smith, Moore & Co's portfolio in Q1 2026, its #58 holding.
- Smith, Moore & Co first reported a position in Eli Lilly in Q3 2017 and has held it in 34 quarters since.
- Smith, Moore & Co's Eli Lilly position peaked at $7.54M in Q2 2024.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.